Literature DB >> 17032962

Superseding psychiatric advance directives: ethical and legal considerations.

Jeffrey W Swanson1, S Van McCrary, Marvin S Swartz, Eric B Elbogen, Richard A Van Dorn.   

Abstract

Psychiatric advance directives (PADs) were introduced in the 1980s as legal instruments for psychiatric patients to retain some choice over their own mental health treatment during periods of decisional incapacity. However, PADs are nested in larger structures of mental health law and policy that protect the interests of parties other than the patient, and which, in situations of conflict involving the treatment of incapacitated patients, tend to favor the clinician's professional judgment over the patient's manifest wishes to avoid standard treatment. Thus, PADs are trumped by civil commitment law and may also be legally overridden by clinicians who, acting in good faith, consider PAD instructions to be inconsistent with accepted clinical standards of care. We discuss philosophical-ethical and legal issues surrounding overriding PADs and offer analysis of the possible future of legal cases in which the question of overriding PADs and fiscal concerns may collide.

Entities:  

Mesh:

Year:  2006        PMID: 17032962

Source DB:  PubMed          Journal:  J Am Acad Psychiatry Law        ISSN: 1093-6793


  3 in total

Review 1.  [Advance directives in patients with mental disorders. Scope, prerequisites for validity, and clinical implementation].

Authors:  J Vollmann
Journal:  Nervenarzt       Date:  2012-01       Impact factor: 1.214

Review 2.  Psychiatric advance directives and social workers: an integrative review.

Authors:  Richard A Van Dorn; Anna Scheyett; Jeffrey W Swanson; Marvin S Swartz
Journal:  Soc Work       Date:  2010-04

Review 3.  Psychiatric Advance Directives and Artificial Intelligence: A Conceptual Framework for Theoretical and Ethical Principles.

Authors:  Stéphane Mouchabac; Vladimir Adrien; Clara Falala-Séchet; Olivier Bonnot; Redwan Maatoug; Bruno Millet; Charles-Siegfried Peretti; Alexis Bourla; Florian Ferreri
Journal:  Front Psychiatry       Date:  2021-01-22       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.